Major Histocompatibility Complex (MHC)-I/II

主要组织相容性复合体-I/II

肿瘤或免疫细胞上的 MHC 能将细胞内的蛋白，包括潜在的新抗原或病毒片段呈递到细胞表面，使免疫系统能识别。

MHC molecules on the surface of tumor or immune cells facilitate the presentation of intracellular proteins, including potential neoantigens or viral fragments. This process enables the immune system to recognize and respond to these cellular components, playing a crucial role in immune surveillance and response.

Get Started

de novo Protein Sequencing

蛋白从头测序

Get Started

我们的蛋白从头测序平台 (de novo protein sequencing) 能够准确鉴定与 MHC 结合的突变肽段 / 新抗原序列，加速靶向药物研发进程。

Our de novo protein sequencing technology can precisely identifies MHC-bound peptides or neo-antigens, accelerating drug development.

> Learn More

肿瘤疫苗

Tumor Vaccine

通过精确鉴定和分析新抗原，研究人员可以针对每位患者肿瘤的独特突变谱设计出高度个性化的肿瘤疫苗。提高疫苗的特异性和有效性，减少对正常组织的影响。

Precise neoantigen identification enables researchers to design personalized cancer vaccines targeting unique tumor mutations. This approach enhances vaccine specificity and efficacy while minimizing effects on normal tissues.

嵌合抗原受体T细胞

CAR-T

新抗原驱动的CAR-T细胞疗法有望克服肿瘤的免疫逃逸机制。经过工程改造的T细胞能够特异性地识别和靶向肿瘤细胞表面的新抗原，从而提高治疗的特异性和效果。

Neoantigen-driven CAR-T therapies offer hope for overcoming tumor immune evasion in refractory cancers. These engineered T cells target tumor-specific neoantigens, improving treatment specificity and efficacy.

双特异性抗体

Bispecific Antibody

双特异性抗体疗法能同时靶向肿瘤细胞表面的新抗原和T细胞上的CD3受体，从而有效将T细胞引导至肿瘤细胞附近，增强免疫系统对肿瘤的识别和杀伤能力。

Neoantigen-driven bispecific antibodies target tumor neoantigens and T cell CD3 receptors, guiding T cells to tumors and activating them. This approach enhances treatment specificity and boosts the immune system's tumor-killing capacity.

Major Histocompatibility Complex (MHC)-I/II

de novo Protein Sequencing

转化应用 (Applications)

肿瘤疫苗

嵌合抗原受体T细胞

双特异性抗体